-+ 0.00%
-+ 0.00%
-+ 0.00%

Actinium Pharmaceuticals begins enrollment in RADIANZ imaging trial for advanced solid tumors

PUBT·11/11/2026 13:03:16
Actinium Pharmaceuticals begins enrollment in RADIANZ imaging trial for advanced solid tumors
  • Actinium Pharmaceuticals began enrolling patients in RADIANZ, an imaging trial guiding development of HER3-targeting radiotherapy ATNM-400 beyond prostate cancer.
  • The study will assess tumor uptake across advanced solid cancers in patients whose disease progressed on standard treatment.
  • Initial prostate cancer results presented at EANM in October 2026 showed no dose-limiting toxicities in the first three patients, supporting dose escalation.
  • Preclinical findings presented at EANM supported broader cancer development; additional breast cancer data will be presented at SABCS on December 8-11, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY94899) on November 11, 2026, and is solely responsible for the information contained therein.